NCT07136844Recruiting
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Source: ClinicalTrials.gov · Last updated 22 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 7 Aug 2025
- Start date
- 29 Mar 2024
- Primary completion date
- Dec 2029
- Lead sponsor
- Centre Hospitalier Universitaire de Liege
- NCT number
- NCT07136844
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 29 Mar 2024 to the primary completion date, Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs
- A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion
Other illness
- Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed
Other
- Non-ambulant patients
- Patients who are participating in an interventional clinical trial
- Pregnant or breastfeeding women
Who the study is looking for
- Ambulant patients (i.e. able to walk 10 meters without assistance)
- Confirmed diagnosis by the investigator based on current gold standard in his/her disease (genetic testing, clinical criteria, etc.)
- Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination.
- Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV.
- Patient with morbid obesity (Body Mass Index\> or = 35 at inclusion visit).
- Signed informed consent form by patient him/herself and patient willing and able to comply with all study procedures.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle Coordinator of this site? Confirm its status | Liège | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.